10x Genomics is trading 4.7% down at $43.45 in after-hours trading after investors may be emphasizing slower reported growth and higher expenses despite raised guidance.
- Second-quarter revenue was $151.0 million, ahead of expectations, and the loss narrowed, but revenue declined from $172.9 million year over year.
- Operating expenses rose 39%, and the company swung to a $17.9 million net loss.
- Management raised 2026 revenue guidance to $610 million-$630 million.